Green Leaf Pharma is a biopharmaceutical manufacturing company specializing in the development of active pharmaceutical ingredients and finished dosage forms of biological drugs using innovative Biopharming technology.
The technology is being developed by an international team of scientists in fields of genetic engineering, molecular biology and pharmaceutical technology based on Russian and Israeli research centers.
In accordance with the Company's plans, the implementation of biopharmaceutical technology in industrial pharmaceutical production allows to create a new kind of effective and safe biosimilars, increase availability of modern methods of treatment, and increase quality of medical care for patients. In 2019 the Green Leaf Pharma has started the development of several pharmaceutical biosimilars of monoclonal antibodies, synthesized in tobacco plants.
The Company's Pipeline includes drugs used in treating cancer, autoimmune and orphan diseases, and medical device based on recombinant human collagen.
Green Leaf Pharma is planning to organize full-cycle production on territory of Russian Federation in full accordance with international GMP and ISO standards, able to meet the demand of Russian market and provide high export potential of manufactured products. The company is focused on cooperation with developers and suppliers of innovative technologies and high-tech materials.
Company is contributing to decision the most relevant healthcare issues and cooperation with state in providing population with effective and safe medicines produced in Russia, in implementing the state programs for developing the pharmaceutical industry and modernizing healthcare.